New Phase 3 trial data on an enhanced influenza vaccine provides practical insights for active adults preparing their immune systems for international travel.
On September 11, 2026, new research in The Lancet Infectious Diseases revealed that a multi technology influenza vaccine generated stronger immune responses in adults aged fifty and older than a traditional enhanced option. For the active adult who values frequent travel, this trial offers important insights into maintaining physical capability during flu season. Long haul flights and crowded group expeditions place significant stress on the aging immune system. This phase 3 study evaluated an immunisation approach designed to address those vulnerabilities, providing a compelling reason to discuss vaccine options with a clinician.
The study evaluated an MF59 adjuvanted, cell derived, higher dose quadrivalent influenza vaccine known as aQIVc. It involved 7,699 adults aged fifty and older across eight countries including the United States and the United Kingdom. The aQIVc formulation combines three distinct technologies to support the immune system. Each dose contained 45 micrograms of haemagglutinin per influenza strain alongside 19.5 milligrams of MF59 adjuvant.
The trial compared aQIVc with two established enhanced influenza vaccine approaches. These comparators included an MF59 adjuvanted egg based quadrivalent vaccine and a recombinant quadrivalent vaccine. The results showed that aQIVc produced superior immune responses compared with the adjuvanted egg based vaccine across all four influenza strains. This superiority held true across all the age groups assessed in the trial.
The trial assessed adults aged fifty and older overall and included a separate analysis of participants aged 65 and older. The results confirmed that aQIVc produced superior immune responses across these specific older age brackets. Active adults in their late sixties and seventies often face the most significant natural changes in immune responsiveness. These specialized trial results offer reassuring evidence that new vaccine technologies can still provoke a strong protective response.
The study also identified stronger exploratory neuraminidase antibody responses with aQIVc than with the comparator vaccines. The clinical significance of these neuraminidase antibodies remains an emerging research question for scientists. It is important to understand the specific scope of these trial results. The published outcome is primarily an immunogenicity and safety result.
The company announcement specifically notes that it does not provide clinical effectiveness, hospitalisation, or mortality outcomes. However, the safety profile of the vaccine is highly relevant for travelers planning immediate departures. The vaccine was described as well tolerated by the trial participants. Most reported reactions were characterised as mild or moderate in severity.
Furthermore, these reactions generally resolved within three days. This is a crucial factor for active adults who cannot afford extended downtime following a pre trip vaccination. The trial was developed by CSL Seqirus, a business of CSL. The organization describes itself as a major influenza vaccine provider with multiple technologies, marketing products in more than 20 countries.
Influenza vaccine development has traditionally relied on singular improvements to existing formulas over time. Professor Colin Russell, chair of the European Scientific Working Group on Influenza, provided commentary on this historical trajectory. He noted that influenza vaccine development has historically advanced through incremental changes. Professor Russell stated that the study is noteworthy because it assesses multiple approaches together in one vaccine.
Gregg Sylvester, the chief medical officer and head of research and development at CSL Seqirus, also highlighted the relevance of the findings. He described the publication as important evidence for healthcare professionals, policymakers, and immunisation advisory groups. These groups are constantly considering future vaccination strategies for older adults. For travelers navigating international health systems, the company announcement notes recent regulatory milestones.
A trivalent formulation of aQIVc has been approved by the UK Medicines and Healthcare products Regulatory Agency for adults aged fifty and older. The trivalent formulation is also approved by the European Commission for adults aged fifty and above. In those specific markets, it is currently marketed as AUJEMFLU. Active adults should be aware that product approvals and local availability can differ significantly by country.
In our experience, international travel tests every system in the human body. After a grueling thirty hour transit to Tokyo, I realized my old strategy of just powering through was no longer working. I felt foggy for three days. I started digging into circadian biology and realized that timing my light exposure and fasting during the flight could completely shift my recovery.
Now, I never board a long haul flight without a precise schedule for when to eat and when to put on an eye mask. It is the difference between losing a week of your trip and hitting the ground running. That exact same principle of rigorous pre trip preparation applies directly to your immune resilience. Managing the physical strain of transit means optimizing your physiological readiness alongside your daily itinerary.
You can learn more about managing these stressors in our guide on understanding the physical strain of long distance transit. Planning ahead keeps you capable and ready for the physical demands of your destination. The findings from this phase 3 trial highlight the importance of proactive immune preparation. Adults planning high altitude hikes, long cruises, or crowded cultural tours face heightened exposure risks in enclosed environments.
The US Department of Health and Human Services advises receiving needed vaccines four to six weeks before departure. This specific timeline ensures the immune response has sufficient time to develop fully. Leaving your vaccination until the last minute can compromise your body's ability to mount a robust defense. Careful preparation ensures that adventure continues to support your long term physical independence.
You can find more practical guidance on maintaining your capability in our comprehensive resource detailing strategies for travel and healthy aging. Travelers must also consider the timing of their trips relative to peak respiratory illness seasons. A late summer departure might conflict with the September or October vaccination window generally favored by CDC guidance for older adults. Early planning helps you navigate these scheduling conflicts without sacrificing your health or your trip.
Active adults should view these immunogenicity findings as a prompt for a personalized medical discussion. Adults aged 65 and older can ask whether a high dose, adjuvanted, or recombinant vaccine is appropriate and available locally. A clear conversation with your doctor will help match the best available option to your specific medical history. Taking a strategic approach to immune health allows you to focus purely on the enjoyment of your expedition.
This proactive mindset is particularly useful when evaluating European travel risks and navigating crowded urban centers. The physical demands of adventure travel often require sustained energy and optimal cardiovascular function. Whether you are skiing challenging alpine routes or trekking across uneven terrain, peak capacity is non negotiable. A severe respiratory infection can easily derail months of careful physical conditioning and planning.
An enhanced influenza vaccine strategy aims to mitigate this specific vulnerability by promoting a stronger immune response. Safeguarding your respiratory health protects the physical stamina required for strenuous outdoor activities. Your clinician can help you weigh the benefits of early vaccination for an impending trip against standard seasonal timing. They can also review your specific destination requirements and confirm which enhanced vaccines are currently in stock.
Product approvals and prescribing rules vary widely depending on your destination country. Active adults should verify that their preferred vaccine formulation is recognized by health authorities at their travel destination. Early coordination ensures you comply with local health guidance while maintaining your personal standard of care. This step is particularly important for group expeditions where organizers require proof of specific medical preparations.
This professional guidance ensures your travel preparations are grounded in sound medical practice rather than guesswork. Prioritizing these conversations transforms health management from a reactive chore into a strategic advantage for your lifestyle. Schedule a vaccination consultation four to six weeks before your next international departure to discuss which enhanced influenza options best protect your physical capability.
Stay connected for research and practical guidance on longevity, strength, recovery, energy and active living. New ideas to help you stay capable, curious and ready for more.
Explore practical guidance on strength, recovery, energy, travel and longevity for a life that stays active.
explore the Blog
